Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (131-140 of 393) with videos related to

Pageof 40
Sort By:
Journal of Cutaneous Medicine and Surgery|November 30, 2024
Development and Validation of Algorithms to Identify Individuals With Cutaneous Lupus From Healthcare DatabasesLisa N Guo, Jordan T Said, Michael J Woodbury, et al.
International Journal of Dermatology|October 30, 2013
Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicityHillary C Frankel, Victoria R Sharon, Ruth Ann Vleugels, et al.
Dermatology and Therapy|September 19, 2023
Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims DatabaseJoseph F Merola, Dhaval Patil, Antton Egana, et al.
Journal of the American Academy of Dermatology|February 7, 2021
Seroconversion of severe acute respiratory syndrome coronavirus 2-infected patients on immunosuppression: A retrospective analysisJeffrey S Smith, Jordan T Said, Scott A Elman, et al.
Journal of Managed Care & Specialty Pharmacy|July 24, 2025
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patternsJoseph F Merola, Sarah Welby, Helena Roque, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) QuestionnaireJeffrey M Cohen, Kareem Halim, Cara J Joyce, et al.
Journal of the American Academy of Dermatology|May 11, 2020
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trialJoseph F Merola, Robert Sidbury, Andreas Wollenberg, et al.
The American Journal of Managed Care|November 14, 2022
Perspectives on nonmedical switching and the COVID-19 pandemic: a narrative reviewJoseph F Merola, April W Armstrong, Sharon Phares, et al.
The Journal of Rheumatology|May 3, 2017
Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual MeetingKristina Callis Duffin, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritisYinzhu Jin, Sarah K Chen, Hemin Lee, et al.
Pageof 40

Showing results (131-140 of 393) with videos related to

Sort By:
Pageof 40
Journal of Cutaneous Medicine and Surgery|November 30, 2024
Development and Validation of Algorithms to Identify Individuals With Cutaneous Lupus From Healthcare DatabasesLisa N Guo, Jordan T Said, Michael J Woodbury, et al.
International Journal of Dermatology|October 30, 2013
Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicityHillary C Frankel, Victoria R Sharon, Ruth Ann Vleugels, et al.
Dermatology and Therapy|September 19, 2023
Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims DatabaseJoseph F Merola, Dhaval Patil, Antton Egana, et al.
Journal of the American Academy of Dermatology|February 7, 2021
Seroconversion of severe acute respiratory syndrome coronavirus 2-infected patients on immunosuppression: A retrospective analysisJeffrey S Smith, Jordan T Said, Scott A Elman, et al.
Journal of Managed Care & Specialty Pharmacy|July 24, 2025
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patternsJoseph F Merola, Sarah Welby, Helena Roque, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) QuestionnaireJeffrey M Cohen, Kareem Halim, Cara J Joyce, et al.
Journal of the American Academy of Dermatology|May 11, 2020
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trialJoseph F Merola, Robert Sidbury, Andreas Wollenberg, et al.
The American Journal of Managed Care|November 14, 2022
Perspectives on nonmedical switching and the COVID-19 pandemic: a narrative reviewJoseph F Merola, April W Armstrong, Sharon Phares, et al.
The Journal of Rheumatology|May 3, 2017
Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual MeetingKristina Callis Duffin, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritisYinzhu Jin, Sarah K Chen, Hemin Lee, et al.
Pageof 40